Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.(PL:SVE)
zł 2.57-0.01 (-0.77%)
PL:SVE
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. financials statements
zł 2.57
At close:-0.01 (-0.77%)
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. (SVE) Ratios
0 Followers
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. Ratios
PL:SVE's free cash flow for Q2 2026 was zł27.00K. For the 2026 fiscal year, PL:SVE's free cash flow was increased by zł65.00K and operating cash flow was zł-38.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.90 | 1.07 | 1.47 | 2.26 | 2.38 |
| Quick Ratio | 0.81 | 0.85 | 0.97 | 1.74 | 1.83 |
| Cash Ratio | 0.01 | 0.02 | 0.07 | 1.11 | 0.83 |
| Solvency Ratio | -0.05 | 0.09 | 0.07 | 0.21 | 0.26 |
| Operating Cash Flow Ratio | 0.05 | 0.32 | -0.17 | 0.12 | -0.19 |
| Short-Term Operating Cash Flow Coverage | 0.09 | 0.74 | -0.68 | 0.43 | -0.90 |
| Net Current Asset Value | zł -17.50M | zł -130.96M | zł -107.69M | zł -2.17M | zł -1.44M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.28 | 0.27 | 0.26 | 0.09 | 0.06 |
| Debt-to-Equity Ratio | 0.68 | 0.66 | 0.62 | 0.14 | 0.09 |
| Debt-to-Capital Ratio | 0.40 | 0.40 | 0.38 | 0.13 | 0.08 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.32 | 0.34 | 0.05 | 0.02 |
| Financial Leverage Ratio | 2.44 | 2.46 | 2.36 | 1.55 | 1.57 |
| Debt Service Coverage Ratio | -0.04 | 0.84 | 1.36 | 1.72 | 2.33 |
| Interest Coverage Ratio | -5.21 | 4.00 | 5.11 | 11.77 | 5.61 |
| Debt to Market Cap | 0.30 | 0.24 | 0.22 | 0.03 | 0.02 |
| Interest Debt Per Share | 1.22 | 1.18 | 1.02 | 0.24 | 0.12 |
| Net Debt to EBITDA | -11.39 | 3.93 | 4.56 | -0.78 | -0.60 |
| Profitability Margins | |||||
| Gross Profit Margin | 30.93% | 61.67% | 60.00% | 56.50% | 55.08% |
| EBIT Margin | -48.98% | 17.76% | 14.10% | 18.22% | 15.91% |
| EBITDA Margin | -17.34% | 28.23% | 25.41% | 30.57% | 31.81% |
| Operating Profit Margin | -48.98% | 17.32% | 14.75% | 19.53% | 17.48% |
| Pretax Profit Margin | -56.92% | 13.44% | 11.21% | 16.57% | 14.32% |
| Net Profit Margin | -47.45% | 10.52% | 8.12% | 12.07% | 10.32% |
| Continuous Operations Profit Margin | -47.45% | 10.52% | 8.12% | 12.07% | 10.32% |
| Net Income Per EBT | 83.36% | 78.30% | 72.43% | 72.86% | 72.10% |
| EBT Per EBIT | 116.20% | 77.60% | 75.97% | 84.80% | 81.94% |
| Return on Assets (ROA) | -6.55% | 2.53% | 1.79% | 3.73% | 3.64% |
| Return on Equity (ROE) | -15.99% | 6.22% | 4.22% | 5.76% | 5.70% |
| Return on Capital Employed (ROCE) | -12.16% | 4.86% | 3.68% | 7.10% | 7.22% |
| Return on Invested Capital (ROIC) | -6.83% | 3.54% | 2.57% | 4.92% | 5.02% |
| Return on Tangible Assets | -6.64% | 2.54% | 1.79% | 3.74% | 3.65% |
| Earnings Yield | -7.53% | 2.37% | 1.59% | 1.55% | 1.52% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.85 | 2.01 | 2.89 | 3.34 | 3.54 |
| Payables Turnover | 13.34 | 1.63 | 8.14 | 8.08 | 10.42 |
| Inventory Turnover | 2.36 | 2.83 | 1.51 | 1.77 | 1.98 |
| Fixed Asset Turnover | 0.26 | 0.30 | 0.28 | 0.52 | 0.65 |
| Asset Turnover | 0.14 | 0.24 | 0.22 | 0.31 | 0.35 |
| Working Capital Turnover Ratio | -8.53 | 8.07 | 2.58 | 1.85 | 3.90 |
| Cash Conversion Cycle | 324.57 | 86.20 | 322.61 | 270.10 | 252.08 |
| Days of Sales Outstanding | 197.58 | 181.65 | 126.36 | 109.19 | 103.00 |
| Days of Inventory Outstanding | 154.35 | 128.98 | 241.11 | 206.09 | 184.11 |
| Days of Payables Outstanding | 27.36 | 224.43 | 44.86 | 45.18 | 35.03 |
| Operating Cycle | 351.93 | 310.63 | 367.48 | 315.28 | 287.11 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.10 | 0.19 | -0.08 | 0.05 | -0.05 |
| Free Cash Flow Per Share | -0.29 | -0.40 | -1.68 | -0.52 | -0.34 |
| Dividend Paid and CapEx Coverage Ratio | 0.26 | 0.31 | -0.05 | 0.08 | -0.18 |
| Capital Expenditure Coverage Ratio | 0.26 | 0.33 | -0.05 | 0.08 | -0.18 |
| Operating Cash Flow Coverage Ratio | 0.09 | 0.17 | -0.08 | 0.19 | -0.51 |
| Operating Cash Flow to Sales Ratio | 0.17 | 0.19 | -0.09 | 0.06 | -0.08 |
| Free Cash Flow Yield | -7.86% | -8.82% | -39.31% | -8.63% | -7.75% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -13.52 | 41.09 | 63.05 | 64.41 | 65.96 |
| Price-to-Sales (P/S) Ratio | 6.30 | 4.44 | 5.12 | 7.77 | 6.81 |
| Price-to-Book (P/B) Ratio | 2.12 | 2.62 | 2.66 | 3.71 | 3.76 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -12.73 | -11.34 | -2.54 | -11.58 | -12.91 |
| Price-to-Operating Cash Flow Ratio | 36.65 | 23.22 | -56.13 | 132.85 | -85.42 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | 0.66 | -2.32 | 1.69 | -11.76 |
| Enterprise Value Multiple | -47.75 | 19.66 | 24.70 | 24.65 | 20.81 |
| Enterprise Value | 347.79M | 398.38M | 367.88M | 379.70M | 272.46M |
| EV to EBITDA | -47.75 | 19.66 | 24.70 | 24.65 | 20.81 |
| EV to Sales | 8.28 | 5.55 | 6.28 | 7.54 | 6.62 |
| EV to Free Cash Flow | -16.71 | -14.17 | -3.12 | -11.23 | -12.55 |
| EV to Operating Cash Flow | 48.14 | 29.02 | -68.83 | 128.80 | -83.04 |
| Tangible Book Value Per Share | 2.22 | 1.70 | 1.60 | 1.61 | 1.17 |
| Shareholders’ Equity Per Share | 1.72 | 1.72 | 1.60 | 1.61 | 1.18 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.17 | 0.22 | 0.28 | 0.27 | 0.28 |
| Revenue Per Share | 0.58 | 1.02 | 0.83 | 0.77 | 0.65 |
| Net Income Per Share | -0.27 | 0.11 | 0.07 | 0.09 | 0.07 |
| Tax Burden | 0.83 | 0.78 | 0.72 | 0.73 | 0.72 |
| Interest Burden | 1.16 | 0.76 | 0.80 | 0.91 | 0.90 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.89 | 0.45 | 0.31 | 0.25 | 0.30 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.36 | 1.82 | -0.81 | 0.35 | -0.56 |
Currency in PLN
